Smithfield Trust Co Has $358,000 Position in AstraZeneca PLC (NASDAQ:AZN)

Smithfield Trust Co raised its holdings in AstraZeneca PLC (NASDAQ:AZN) by 11.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,619 shares of the company’s stock after purchasing an additional 471 shares during the quarter. Smithfield Trust Co’s holdings in AstraZeneca were worth $358,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. McClarren Financial Advisors Inc. grew its position in AstraZeneca by 320.8% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after acquiring an additional 247 shares during the last quarter. GHP Investment Advisors Inc. bought a new position in AstraZeneca in the 2nd quarter valued at approximately $26,000. Capital Performance Advisors LLP bought a new stake in AstraZeneca during the 3rd quarter worth approximately $28,000. Pathway Financial Advisers LLC acquired a new position in AstraZeneca in the 1st quarter valued at approximately $29,000. Finally, CANADA LIFE ASSURANCE Co lifted its holdings in shares of AstraZeneca by 40.6% during the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock worth $34,000 after purchasing an additional 146 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Price Performance

Shares of NASDAQ AZN opened at $64.13 on Friday. The stock has a fifty day moving average of $73.69 and a 200-day moving average of $77.86. The stock has a market cap of $198.83 billion, a PE ratio of 30.68, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68.

AstraZeneca (NASDAQ:AZN) last posted its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.03. The business had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.87 EPS. Equities research analysts anticipate that AstraZeneca PLC will post 4.1 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on AZN. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Finally, TD Cowen upped their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.